Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection
August 24, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights
August 12, 2015 16:05 ET
|
Argos Therapeutics, Inc.
- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial...
Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma
August 10, 2015 13:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Hold Second Quarter 2015 Financial Results Conference Call on Wednesday, August 12, 2015
August 05, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics Announces Formation of Scientific Advisory Board
July 21, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., July 21, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 17, 2015 08:30 ET
|
Argos Therapeutics, Inc.
The company's director of molecular biology to participate in roundtable discussion at the "Towards an HIV Cure" symposium
DURHAM, N.C., July 17, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc....
Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003
July 15, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., July 15, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
Argos Therapeutics to Present at the 2015 JMP Securities Life Sciences Conference
June 16, 2015 16:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., June 16, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of fully personalized...
Argos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations
June 15, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., June 15, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
Independent Data Monitoring Committee Recommends Continuation of Pivotal ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma
June 04, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., June 4, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...